Canagliflozin: First Global Approval

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

(2012) D. Devineni et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

(2012) Yin Liang et al.   PLoS One

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

(2011) S. Sha et al.   DIABETES OBESITY & METABOLISM

Renal glucose reabsorption inhibitors to treat diabetes

(2011) Clifford J. Bailey   TRENDS IN PHARMACOLOGICAL SCIENCES

Sodium-Glucose Co-Transport Inhibitors

(2010) Joshua J. Neumiller et al.   DRUGS